[Chemotherapy for brain metastases].
Narita
Yoshitaka
Y
Neurosurgery Division, National Cancer Center Hospital.
D000927:Anticonvulsants / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001812:Blood-Brain Barrier / Q000378:metabolism; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000556:secondary*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000556:secondary*; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000627:therapeutic use; D015140:Dementia, Vascular / Q000209:etiology; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary*; D008665:Metalloporphyrins / Q000627:therapeutic use; D011239:Prednisolone / Q000009:adverse effects; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D018714:Radiotherapy, Adjuvant; D000077204:Temozolomide
D000927:Anticonvulsants; D008665:Metalloporphyrins; D011838:Radiation-Sensitizing Agents; C437683:motexafin gadolinium; D003606:Dacarbazine; D011239:Prednisolone; D000077204:Temozolomide